Overview

An Exploratory Open Label Study of EPI-743 (Vincerinone TM) in Children With Autism Spectrum Disorder

Status:
Withdrawn
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
The investigators hypothesize that EPI-743 may provide clinical benefit to children with Autism Spectrum Disorder.
Phase:
Phase 2
Details
Lead Sponsor:
Edison Pharmaceuticals Inc
Treatments:
Ubiquinone